Pharmaron Acquires Bridge China To Become Fully-integrated CRO
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Pharmaron, a Beijing-headquartered contact research organization, announced Jan. 11 that it has acquired Bridge Laboratories China, a leading preclinical CRO in China, to add toxicology services to its portfolio